With a growing number of overweight individuals now obtaining Sanofi's diet drug Acomplia (rimonabant) from Europe, a forum to enable readers to report on weight-loss results, side-effects, and experiences in buying the diet pill outside the U.S. has been launched by the newsletter Acomplia Report.

"We decided to start the Acomplia Report Forum after receiving a growing volume of email from patients now taking Acomplia who are anxious to compare experiences with others," said publisher Milton R. Benjamin.

"While the Acomplia Report's primary mission will continue to be to report on the regulatory process and issues involved in the approval and marketing of this highly anticipated diet drug, our reporting staff will now be augmented by hundreds of Acomplia users reporting on their own experiences," he added.

In the week since the Acomplia Report Forum was launched, a number of users of the weight-loss drug -- as well as physicians in both Europe and the United States -- have registered to participate in discussions on the site, and the forum already is prompting the liveliest exchange of information on rimonabant found on the Internet.

"We are very hopeful that the Acomplia Report Forum will continue to attract users seriously interested in the use of this highly anticipated drug to treat a serious medical condition, and that the forum will become an important resource for the exchange of helpful and potentially life-transforming information," Benjamin said.